229 related articles for article (PubMed ID: 18181051)
21. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Cohen EE
J Clin Oncol; 2006 Jun; 24(17):2659-65. PubMed ID: 16763280
[TBL] [Abstract][Full Text] [Related]
22. The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer.
Koukourakis G; Kouloulias V; Koukourakis M; Kouvaris J; Zacharias G; Gouliamos A
J BUON; 2009; 14(1):19-25. PubMed ID: 19373942
[TBL] [Abstract][Full Text] [Related]
23. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
24. EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?
Alorabi M; Shonka NA; Ganti AK
Crit Rev Oncol Hematol; 2016 Mar; 99():170-9. PubMed ID: 26797287
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab in non-melanoma skin cancer.
Wollina U
Expert Opin Biol Ther; 2012 Jul; 12(7):949-56. PubMed ID: 22519406
[TBL] [Abstract][Full Text] [Related]
26. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS; Hong WK
Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
[TBL] [Abstract][Full Text] [Related]
27. Aberrant kinase signaling: lessons from head and neck cancer.
Nelson EG; Grandis JR
Future Oncol; 2007 Jun; 3(3):353-61. PubMed ID: 17547530
[TBL] [Abstract][Full Text] [Related]
28. Pharmacotherapy of head and neck squamous cell carcinoma.
Pan Q; Gorin MA; Teknos TN
Expert Opin Pharmacother; 2009 Oct; 10(14):2291-302. PubMed ID: 19663637
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor targeted therapies for solid tumours.
Van den Eynde M; Baurain JF; Mazzeo F; Machiels JP
Acta Clin Belg; 2011; 66(1):10-7. PubMed ID: 21485758
[TBL] [Abstract][Full Text] [Related]
30. Is there a role for cetuximab in non small cell lung cancer?
Morgensztern D; Govindan R
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4602-5. PubMed ID: 17671149
[TBL] [Abstract][Full Text] [Related]
31. Radiation combined with EGFR signal inhibitors: head and neck cancer focus.
Harari PM; Huang S
Semin Radiat Oncol; 2006 Jan; 16(1):38-44. PubMed ID: 16378905
[TBL] [Abstract][Full Text] [Related]
32. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?
Bernier J; Schneider D
Eur J Cancer; 2007 Jan; 43(1):35-45. PubMed ID: 17098420
[TBL] [Abstract][Full Text] [Related]
33. Molecular-targeted therapies in head and neck cancer.
Rao SD; Fury MG; Pfister DG
Semin Radiat Oncol; 2012 Jul; 22(3):207-13. PubMed ID: 22687945
[TBL] [Abstract][Full Text] [Related]
34. Emerging drugs for head and neck cancer.
Rhee JC; Khuri FR; Shin DM
Expert Opin Emerg Drugs; 2004 May; 9(1):91-104. PubMed ID: 15155138
[TBL] [Abstract][Full Text] [Related]
35. Molecular-targeted therapy of head and neck squamous cell carcinoma: beyond cetuximab-based therapy.
Machiels JP; Schmitz S
Curr Opin Oncol; 2011 May; 23(3):241-8. PubMed ID: 21358328
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor directed therapy in head and neck cancer.
Choong NW; Cohen EE
Crit Rev Oncol Hematol; 2006 Jan; 57(1):25-43. PubMed ID: 16207530
[TBL] [Abstract][Full Text] [Related]
37. Molecular targeted therapy of head and neck cancer: review and clinical development challenges.
Le Tourneau C; Faivre S; Siu LL
Eur J Cancer; 2007 Nov; 43(17):2457-66. PubMed ID: 17904355
[TBL] [Abstract][Full Text] [Related]
38. Transforming growth factor alpha stimulation of mucosal tissue cultures from head and neck squamous cell carcinoma patients increases chemoresistance to cisplatin.
Baumeister P; Reiter M; Schwenk-Zieger S; Harréus U
Chemotherapy; 2010; 56(4):268-74. PubMed ID: 20693797
[TBL] [Abstract][Full Text] [Related]
39. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Herbst RS; Arquette M; Shin DM; Dicke K; Vokes EE; Azarnia N; Hong WK; Kies MS
J Clin Oncol; 2005 Aug; 23(24):5578-87. PubMed ID: 16009949
[TBL] [Abstract][Full Text] [Related]
40. Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor.
Mandic R; Rodgarkia-Dara CJ; Zhu L; Folz BJ; Bette M; Weihe E; Neubauer A; Werner JA
FEBS Lett; 2006 Sep; 580(20):4793-800. PubMed ID: 16904111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]